306 related articles for article (PubMed ID: 38501105)
21. Targeted Therapy and Personalized Medicine.
Saeed RF; Awan UA; Saeed S; Mumtaz S; Akhtar N; Aslam S
Cancer Treat Res; 2023; 185():177-205. PubMed ID: 37306910
[TBL] [Abstract][Full Text] [Related]
22. Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
Ma LX; Espin-Garcia O; Bedard PL; Stockley T; Prince R; Mete O; Krzyzanowska MK
Thyroid; 2022 Jun; 32(6):657-666. PubMed ID: 35262412
[No Abstract] [Full Text] [Related]
23. LncRNAs as Potential Therapeutic Targets in Thyroid Cancer.
Javed Z; Ahmed Shah F; Rajabi S; Raza Q; Iqbal Z; Ullah M; Ahmad T; Salehi B; Sharifi-Rad M; Pezzani R; Yaqoob F; Sadia H; Iriti M; Sharifi-Rad J; Cho WC
Asian Pac J Cancer Prev; 2020 Feb; 21(2):281-287. PubMed ID: 32102500
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib in Metastatic Papillary Thyroid Carcinoma with
Caterino M; Pirozzi M; Facchini S; Zotta A; Sica A; Lo Giudice G; Rauso R; Varriale E; Ciardiello F; Fasano M
Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630083
[TBL] [Abstract][Full Text] [Related]
25. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.
Chu YH; Wirth LJ; Farahani AA; Nosé V; Faquin WC; Dias-Santagata D; Sadow PM
Mod Pathol; 2020 Dec; 33(12):2458-2472. PubMed ID: 32737449
[TBL] [Abstract][Full Text] [Related]
27. DNA methylation in thyroid cancer.
Zafon C; Gil J; Pérez-González B; Jordà M
Endocr Relat Cancer; 2019 Jul; 26(7):R415-R439. PubMed ID: 31035251
[TBL] [Abstract][Full Text] [Related]
28. The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.
Kasaian K; Wiseman SM; Walker BA; Schein JE; Zhao Y; Hirst M; Moore RA; Mungall AJ; Marra MA; Jones SJ
BMC Cancer; 2015 Dec; 15():984. PubMed ID: 26680454
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer.
Chou CK; Liu RT; Kang HY
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28294980
[TBL] [Abstract][Full Text] [Related]
30. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.
Viola D; Valerio L; Molinaro E; Agate L; Bottici V; Biagini A; Lorusso L; Cappagli V; Pieruzzi L; Giani C; Sabini E; Passannati P; Puleo L; Matrone A; Pontillo-Contillo B; Battaglia V; Mazzeo S; Vitti P; Elisei R
Endocr Relat Cancer; 2016 Apr; 23(4):R185-205. PubMed ID: 27207700
[TBL] [Abstract][Full Text] [Related]
31. Differentiated thyroid cancer-personalized therapies to prevent overtreatment.
Luster M; Weber T; Verburg FA
Nat Rev Endocrinol; 2014 Sep; 10(9):563-74. PubMed ID: 24981455
[TBL] [Abstract][Full Text] [Related]
32. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
33.
Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
[No Abstract] [Full Text] [Related]
34. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
[TBL] [Abstract][Full Text] [Related]
35. Heat shock proteins in thyroid malignancies: Potential therapeutic targets for poorly-differentiated and anaplastic tumours?
Lettini G; Pietrafesa M; Lepore S; Maddalena F; Crispo F; Sgambato A; Esposito F; Landriscina M
Mol Cell Endocrinol; 2020 Feb; 502():110676. PubMed ID: 31812782
[TBL] [Abstract][Full Text] [Related]
36. Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations.
Abdullah MI; Junit SM; Ng KL; Jayapalan JJ; Karikalan B; Hashim OH
Int J Med Sci; 2019; 16(3):450-460. PubMed ID: 30911279
[TBL] [Abstract][Full Text] [Related]
37. Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study.
Lazure P; Sireci A; Subbiah V; Murray S; Grohé C; Sherman SI; Kelly E; Bubach P; Péloquin S
BMC Med Educ; 2023 Jun; 23(1):410. PubMed ID: 37277734
[TBL] [Abstract][Full Text] [Related]
38. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.
Sicklick JK; Fanta PT; Shimabukuro K; Kurzrock R
Cancer Metastasis Rev; 2016 Jun; 35(2):263-75. PubMed ID: 26857926
[TBL] [Abstract][Full Text] [Related]
39. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
40. How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review.
Seo MK; Cairns J
BMC Cancer; 2021 Sep; 21(1):980. PubMed ID: 34470603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
